Bleomycin A2

DB19091InvestigationalSmall molecule

Bleomycin A2 is under investigation in clinical trial NCT00026208 (Combination Chemotherapy Plus Low-dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma).

Formula / weight: C₅₅H₈₃N₁₇O₂₁S₃ · 1414.55 g/mol (avg)
Also known as: Bleogin · Bleomycinamide, n1-(3-(dimethylsulfonio)propyl)- · Pingyangmycin a2 · Zhengguangmycin a2

Resolves to

Compound

UNII13M89UEA7WCAS11116-31-7

Structure

InChIKeyOYVAGSVQBOHSSS-UAPAGMARSA-NSMILES

[H][C@]1(O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2O[C@H]([C@H](NC(=O)C2=NC(=NC(N)=C2C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC2=NC(=CS2)C2=NC(=CS2)C(=O)NCCC[S+](C)C)C2=CN=C[N-]2)O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Bleomycin A2, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account